Mazdutide (Synonyms: IBI-362; LY-3305677; OXM-3) |
Catalog No.GC69439
One-Click Copy Product Info
|
Mazdutide is a long-acting dual agonist of the glucagon-like peptide-1 receptor (GLP-1R; Ki=28.6nM) and the glucagon receptor (GCGR; Ki=17.7nM).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2259884-03-0
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Mazdutide is a long-acting dual agonist of the glucagon-like peptide-1 receptor (GLP-1R; Ki=28.6nM) and the glucagon receptor (GCGR; Ki=17.7nM)[1-2]. Mazdutide can suppress appetite and slow gastric emptying by activating the GLP-1 receptor to reduce energy intake, while simultaneously increasing energy expenditure and promoting hepatic fat breakdown by activating the GCG receptor to improve metabolism. Mazdutide is used for the long-term management of adult overweight/obesity and the treatment of type 2 diabetes[3-4].
In vivo, db/db mice were subcutaneously administered Mazdutide (50-200μg/kg) once every three days for 12 consecutive weeks. Mazdutide significantly improved diabetes-associated cognitive dysfunction[5]. C57BL/6J male mice with obesity induced by a 13-week high-fat diet were subcutaneously administered Mazdutide (15nmol/kg) once every three days for 4 weeks. Mazdutide significantly reduced hepatic fat accumulation, and its effect was superior to that of a GLP-1R mono-agonist[6].
References:
[1] Shirley M. Mazdutide: First Approval. Drugs. 2025 Dec;85(12):1621-1627.
[2] Pan XF, Fang ZZ, Zhang L, et al. Obesity in China: current progress and future prospects. Lancet Diabetes Endocrinol. 2026 Feb;14(2):178-186.
[3] Bailey CJ, Flatt PR, Conlon JM. Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities. Peptides. 2025 May;187:171380.
[4] Sidrak WR, Kalra S, Kalhan A. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article. Indian J Endocrinol Metab. 2024 Sep-Oct;28(5):445-460.
[5] Dong W, Bai J, Yuan Q, Z, et al. Mazdutide, a dual agonist targeting GLP-1R and GCGR, mitigates diabetes-associated cognitive dysfunction: mechanistic insights from multi-omics analysis. EBioMedicine. 2025 Jul;117:105791.
[6] Xia H, Min Y, Wang Y, et al. Multiparametric MRI Evaluation of Liver Fat and Iron after Glucagon-like Peptide-1 Receptor and Glucagon Receptor Dual-Agonist Treatment in a High-Fat Diet-induced Mouse Model. Radiology. 2025 Aug;316(2):e243780.
| Animal experiment [1]: | |
Animal models | db/db mice |
Preparation Method | Male db/db mice were subcutaneously administered three escalating doses of Mazdutide (50, 100, 200μg/kg) or dulaglutide (200μg/kg) once every three days for 12 weeks. Cognitive function, metabolic parameters, brain pathology, and molecular pathways were evaluated at the end of treatment. |
Dosage form | 50, 100, 200μg/kg; s.c.; Once every three days for 12 weeks. |
Applications | Mazdutide administration led to significant body weight loss, improved glycemic control, and ameliorated diabetes-associated cognitive dysfunction. Mazdutide improved performance in behavioral tests, reduced neuronal injury and myelin decline in the hippocampus, and modulated pathways related to neurotransmission, neuroinflammation, and synaptic plasticity. |
References: | |
| Cas No. | 2259884-03-0 | SDF | |
| Synonyms | IBI-362; LY-3305677; OXM-3 | ||
| Formula | M.Wt | 4563.06 | |
| Solubility | H2O : 22.22 mg/mL (ultrasonic and adjust pH to 2 with HCl) | Storage | Store at -20°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 219.2 μL | 1.0958 mL | 2.1915 mL |
| 5 mM | 43.8 μL | 219.2 μL | 438.3 μL |
| 10 mM | 21.9 μL | 109.6 μL | 219.2 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >99.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)